[Corrigendum] Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth
Affiliations: Department of Pharmacology and Toxicology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China, Department of Production Technology, Shandong Buchang Shenzhou Pharmaceutical Co., Ltd., Heze 274000, P.R. China
- Published online on: October 23, 2023 https://doi.org/10.3892/ijo.2023.5583
- Article Number: 135
Copyright : © Xuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].